title: [Thrombotic events and significance of the IPSET thrombosis risk evaluation score in essential thrombocythaemia].
abstract: BACKGROUND
  Thrombo-haemorrhagic complications contribute to both morbidity and mortality in patients with essential thrombocythaemia.
  
  
  OBJECTIVE
  The aim of the authors was to estimate the incidence of thrombotic events and to examine the clinical utility of IPSET thrombosis risk evaluation score against conventional two-categorical (low and high) risk assessment.
  
  
  METHODS
  A retrospective analysis was carried out on 155 patients with essential thrombocythaemia (106 females; median age, 61 years) in a period between 1999 and 2014.
  
  
  RESULTS
  The analysis revealed 55 (35.5%) major thrombotic events before and 25 (16.1%) major thrombotic complications after establishment of the haematologic diagnosis. Significant differences were observed in thrombosis-free survival between the different IPSET groups (p = 0.002).
  
  
  CONCLUSIONS
  The IPSET model was first examined in this cohort of patients with essential thrombocythaemia diagnosed in a single Hungarian haematologic centre. The results suggest that this score may provide more information than the conventional thrombosis risk assessment.
authors.affiliation: Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ, Általános Orvostudományi Kar II. Belgyógyászati Klinika és Kardiológiai Központ, Haematológiai Osztály Szeged.
authors.forename: Éva
authors.initials: É
authors.lastname: Pósfai
authors.affiliation: Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ, Általános Orvostudományi Kar II. Belgyógyászati Klinika és Kardiológiai Központ, Haematológiai Osztály Szeged.
authors.forename: Imelda
authors.initials: I
authors.lastname: Marton
authors.affiliation: Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ, Általános Orvostudományi Kar II. Belgyógyászati Klinika és Kardiológiai Központ Szeged Semmelweis utca 6. 6720.
authors.forename: Attila
authors.initials: A
authors.lastname: Nemes
authors.affiliation: Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ, Általános Orvostudományi Kar II. Belgyógyászati Klinika és Kardiológiai Központ, Haematológiai Osztály Szeged.
authors.forename: Zita
authors.initials: Z
authors.lastname: Borbényi
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001772:Blood Cell Count; D048909:Diabetes Complications / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006529:Hepatomegaly / Q000453:epidemiology; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D006949:Hyperlipidemias / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D013163:Splenomegaly / Q000453:epidemiology; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000175:diagnosis*; D013927:Thrombosis / Q000453:epidemiology* / Q000209:etiology*
keywords: IPSET; JAK2 V617F mutation; JAK2 V617F-mutáció; cardiovascular risk factors; cardiovascularis kockázati faktorok; essential thrombocythaemia; essentialis thrombocythaemia; myeloproliferativ neoplasia; myeloproliferative neoplasm; thrombosis